

## Ultomiris (ravulizumab-cwvz)

### Disclaimer

*Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.*

*Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.*

### Summary

Ultomiris (ravulizumab-cwvz) is a humanized monoclonal antibody that specifically binds to the complement protein C5, inhibiting its cleavage into C5a and C5b, thereby preventing the generation of the terminal complement complex C5b-9. By inhibiting the terminal complement pathway, Ultomiris (ravulizumab-cwvz) reduces intravascular hemolysis in PNH, complement-mediated TMA in aHUS, anti-AChR antibody-induced complement damage at the neuromuscular junction (NMJ) in gMG, and aquaporin-4 antibody-induced complement-mediated damage in NMOSD. Ultomiris (ravulizumab-cwvz) is FDA-approved for:

- Treatment of PNH and aHUS in adults and children  $\geq$  1 month of age
- Treatment of anti-AChR antibody positive gMG in adults
- Treatment of anti-AQP4 antibody positive NMOSD in adults

## Definitions

"**Atypical hemolytic uremic syndrome (aHUS)**" is an ultra-rare, life-threatening genetic disorder caused by chronic, uncontrolled activation of the alternative complement pathway, resulting in complement-mediated thrombotic microangiopathy (TMA).

"**Generalized myasthenia gravis (gMG)**" is an autoimmune neuromuscular disease caused by antibodies that attack components of the neuromuscular junction (NMJ), impairing transmission between nerve and muscle, resulting in muscle weakness and fatigue.

"**Myasthenia Gravis Activities of Daily Living (MG-ADL) score**" is a validated, 8-item patient-reported scale that assesses the impact of myasthenia gravis on daily functions.

"**Myasthenia Gravis Foundation of America (MGFA) Clinical Classification**" is a commonly used classification system that defines myasthenia gravis severity based on the degree and distribution of muscle weakness.

"**Neuromyelitis optica spectrum disorder (NMOSD)**" is a rare autoimmune disorder of the central nervous system that primarily affects the optic nerves and spinal cord, characterized by inflammation and demyelination caused by aquaporin-4 antibodies.

"**Paroxysmal nocturnal hemoglobinuria (PNH)**" refers to a rare, acquired, life-threatening disease of the blood characterized by complement-mediated hemolysis, thrombosis, and bone marrow failure.

"**Quantitative Myasthenia Gravis (QMG) score**" is a 13-item physician-administered scale that measures the severity of myasthenia gravis based on muscle weakness assessment.

## Medical Necessity Criteria for Initial Authorization

The Plan considers **Ultomiris (ravulizumab-cwvz)** medically necessary when **ALL** the following criteria are met for the applicable indication listed below:

1. Prescribed by, or in consultation with, a physician who specializes in the treatment of the specific condition:
  - a. Atypical hemolytic uremic syndrome (aHUS) - hematologist or nephrologist; **or**
  - b. Generalized myasthenia gravis (gMG) - neurologist or neuromuscular disease specialist;  
**or**
  - c. Paroxysmal Nocturnal Hemoglobinuria (PNH) - hematologist; **or**

- d. Neuromyelitis optica spectrum disorder (NMOSD) - neurologist; **AND**
- 2. Will not be used concomitantly with other immunomodulatory biologic therapies (e.g., eculizumab, efgartigimod alfa, rituximab, rozanolixizumab, zilucoplan, etc.); **AND**
- 3. Dosing is consistent with FDA-approved labeling **OR** is supported by compendia or evidence-based published dosing guidelines based on indication, weight, and age; **AND**
- 4. The member meets the medical necessity criteria for the applicable indication listed below:

**For members currently receiving Soliris (eculizumab):**

- 5. The member has a confirmed diagnosis of ONE of the following:
  - a. Atypical hemolytic uremic syndrome (aHUS); **or**
  - b. Generalized myasthenia gravis (gMG); **or**
  - c. Neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive;  
**or**
  - d. Paroxysmal Nocturnal Hemoglobinuria (PNH); **AND**
- 6. The member is currently receiving treatment with Soliris (eculizumab); **AND**
- 7. The member has had an adequate response to Soliris (eculizumab) therapy, as evidenced by improvement or stabilization in disease-related signs and symptoms specific to their condition.

**Atypical hemolytic uremic syndrome (aHUS)**

- 5. The member is at least 1 month of age; **AND**
- 6. The member has a diagnosis of diagnosis of aHUS confirmed by ruling out:
  - a. Thrombotic thrombocytopenic purpura (TTP), e.g., ADAMTS13 activity level above 5%;  
**and**
  - b. Shiga toxin E. coli-related HUS (STEC-HUS), e.g., STEC-test negative in members with a history of bloody diarrhea in the preceding 2-weeks; **AND**
- 7. The member has documented presence of thrombotic microangiopathy, as evidenced by ALL of the following:
  - a. Microangiopathic hemolytic anemia (e.g., anemia, increased LDH, decreased haptoglobin, increased indirect bilirubin, increased AST, elevated reticulocyte count, presence of schistocytes, helmet cells, and burr cells on peripheral blood smear); **and**
  - b. Thrombocytopenia, defined as a platelet count below 150,000/microliter; **and**
  - c. Acute kidney injury (e.g., elevated serum creatinine, oliguria, presence of hematuria, proteinuria, pyuria, casts on urinalysis) or member requires dialysis.

### **Generalized myasthenia gravis (gMG)**

5. The member is 18 years of age or older; **AND**
6. The member has a confirmed diagnosis of generalized myasthenia gravis (gMG) **AND** documentation of **ALL** of the following:
  - a. Positive serologic test for anti-acetylcholine receptor (anti-AChR) antibodies; **and**
  - b. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IV (see **Appendix, Table 1**); **and**
  - c. Baseline Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score of at least ( $\geq$ ) 6; **AND**
7. The member is unable to use, limited by toxicity, or has adequately tried and failed or experienced insufficient response to at least **TWO** standard therapies for gMG, such as:
  - a. Cholinesterase inhibitors (eg, pyridostigmine); **and/or**
  - b. Corticosteroids (e.g., prednisone) or inability to taper steroids below a reasonably acceptable level without return of symptoms; **and/or**
  - c. Immunosuppressive therapies (e.g., azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide, tacrolimus).

### **Neuromyelitis Optica Spectrum Disorder (NMOSD)**

5. The member is 18 years of age or older; **AND**
6. The member has confirmed diagnosis of NMOSD, as evidenced by a positive serologic test for anti-aquaporin-4 (AQP4) antibodies; **AND**
7. The member must have experienced at least **ONE** of the following:
  - a. 2 or more relapses in the 12 months prior; **or**
  - b. 3 or more relapses in the 24 months prior, with at least 1 relapse occurring within the last 12 months; **AND**
8. The member has an Expanded Disability Status Scale (EDSS) score of  $\leq 7$  (i.e., presence of at least limited ambulation with aid).

### **Paroxysmal Nocturnal Hemoglobinuria (PNH)**

5. The member is at least 1 month of age; **AND**
6. Diagnosis of PNH confirmed by flow cytometry demonstrating a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) with EITHER of the following:
  - a. at least 5% PNH cells; **or**
  - b. at least 51% of GPI-deficient poly-morphonuclear cells; **AND**
7. The member has documentation of one or more of the following:
  - a. Hemoglobin  $\leq 9$  g/dL with symptomatic anemia, or hemoglobin  $\leq 7$  g/dL; **and/or**

- b. Absolute reticulocyte count  $\geq$  2 times the upper limit of normal; **and/or**
- c. Thrombosis; **and/or**
- d. Transfusion dependence ( $\geq$  2 transfusions in the last 12 months).

**If the above prior authorization criteria are met, Ultomiris (ravulizumab-cwvz) will be authorized for 6-months.**

### Medical Necessity Criteria for Reauthorization

Reauthorization for 12-months will be granted if the member has recent (within the last 3 months) clinical chart documentation demonstrating **ALL** of the following criteria:

1. Prescribed by, or in consultation with, a physician who specializes in the treatment of the specific condition:
  - a. Atypical hemolytic uremic syndrome (aHUS) - hematologist or nephrologist; **or**
  - b. Generalized myasthenia gravis (gMG) - neurologist or neuromuscular disease specialist;  
**or**
  - c. Paroxysmal Nocturnal Hemoglobinuria (PNH) - hematologist; **AND**
2. There is no unacceptable toxicity or adverse reaction to therapy, such as:
  - a. Serious infections (e.g. serious respiratory or urinary tract infections); **and/or**
  - b. Severe hypersensitivity reactions; **and/or**
  - c. Severe immunosuppression; **and/or**
  - d. Other intolerable side effects or reactions; **AND**
3. Will not be used concomitantly with other immunomodulatory biologic therapies (e.g., eculizumab, efgartigimod alfa, rituximab, rozanolixizumab, zilucoplan, etc.); **AND**
4. Dosing is consistent with FDA-approved labeling **OR** is supported by compendia or evidence-based published dosing guidelines based on indication, weight, and age; **AND**
5. Ongoing therapy is required to maintain disease stability and control; **AND**
6. Documentation of positive clinical response to therapy, such as ANY of the following:
  - a. Atypical Hemolytic Uremic Syndrome (aHUS)
    - i. Improvement or normalization of lactate dehydrogenase (LDH) levels and/or haptoglobin; **and/or**
    - ii. Improvement or normalization of platelet counts; **and/or**
    - iii. Improvement in serum creatinine from baseline and/or stabilization of renal function; **and/or**
    - iv. Reduction or absence of schistocytes or fragmented red blood cells on peripheral blood smear; **and/or**

- v. Improvement in hemoglobin levels from baseline; **or**
- b. Generalized Myasthenia Gravis
  - i. Improvement in Myasthenia Gravis-Activities of Daily Living (MG-ADL) **OR** Quantitative Myasthenia Gravis (QMG) score from baseline; **and/or**
  - ii. Achievement of minimal symptom expression or pharmacological remission; **and/or**
  - iii. Lack of relapses or reduced frequency/severity of relapses compared to baseline; **or**
- c. Neuromyelitis Optica Spectrum Disorder (NMOSD)
  - i. Absence of new lesions on MRI; **and/or**
  - ii. Improvement or stabilization of neurologic symptoms; **and/or**
  - iii. Reduction in relapse frequency/severity; **and/or**
  - iv. Reduced hospitalizations; **and/or**
  - v. Reduction/discontinuation in plasma exchange treatment; **or**
- d. Paroxysmal Nocturnal Hemoglobinuria (PNH)
  - i. Stabilization of hemoglobin levels; **and/or**
  - ii. Decreased transfusion requirements; **and/or**
  - iii. Reduced hemolysis; **and/or**
  - iv. Improvement in PNH symptoms; **and/or**
  - v. Improvement or normalization of lactate dehydrogenase (LDH) levels.

### Experimental or Investigational / Not Medically Necessary

Ultomiris (ravulizumab-cwvz) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Concomitant use with other targeted immunomodulating biologics.
- Other complement-mediated diseases or conditions not listed above as medically necessary.
- Prevention of delayed graft function (DGF) in kidney transplant recipients.
- Shiga toxin Escherichia coli related hemolytic uremic syndrome (STEC-HUS).
- Subcutaneous administration for the treatment of generalized myasthenia gravis.
- Subcutaneous administration in pediatric members for any indication.
- Treatment of amyotrophic lateral sclerosis (ALS).
- Treatment of thrombotic thrombocytopenic purpura (TTP).
- Use in members who have unresolved serious *Neisseria meningitidis* infection or are not adequately vaccinated against *Neisseria meningitidis*.

## Applicable Billing Codes (HCPCS/CPT Codes)

<b>Service(s) name</b>	
<b>CPT/HCPCS Codes considered medically necessary if criteria are met:</b>	
<i>Code</i>	<i>Description</i>
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
J1303	Injection, ravulizumab-cwvz, 10 mg
<b>ICD-10 codes considered medically necessary if criteria are met:</b>	
<i>Code</i>	<i>Description</i>
D59.3	Hemolytic-uremic syndrome
D59.30	Hemolytic-uremic syndrome, unspecified
D59.31	Infection-associated hemolytic-uremic syndrome
D59.32	Hereditary hemolytic-uremic syndrome
D59.39	Other hemolytic-uremic syndrome
D59.5	Paroxysmal nocturnal hemoglobinuria
G36.0	Neuromyelitis optica
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation

## Appendix

**Table 1: Summary of Myasthenia Gravis Foundation of America (MGFA) Disease Clinical Classification**

<b><i>Class</i></b>	<b><i>Description</i></b>
<b>I</b>	Ocular muscle weakness; All other muscles - normal strength
<b>II</b>	Mild generalized weakness
<b>IIa</b>	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
<b>IIb</b>	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
<b>III</b>	Moderate generalized weakness
<b>IIIa</b>	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
<b>IIIb</b>	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
<b>IV</b>	Severe generalized weakness
<b>IVa</b>	Predominantly limb/axial weakness; Lesser oropharyngeal involvement possible
<b>IVb</b>	Predominantly oropharyngeal/respiratory weakness; Lesser limb/axial involvement possible
<b>V</b>	Intubation, with or without ventilation; Not for routine postoperative care

**NOTE:** The preceding table summarizes key aspects of the Myasthenia Gravis Foundation of America (MGFA) Disease Classifications. This is provided only for quick reference. For the exact definitions and details on the MGFA Disease Classifications, please refer to the original MGFA Classification document available at <https://myasthenia.org/Portals/0/MGFA%20Classification.pdf>.

## References

1. Ariceta G, Dixon B, Kim S, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. *Kidney Int.* 2021;100:225-237.
2. Barbour T, Scully M, Ariceta G, et al. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. *Kidney Int Rep.* 2021;6(6):1603-1613. doi:10.1016/j.ekir.2021.03.884



3. Chang, Chih-Hsiang; Lin, Chan-Yu; Tian, Ya-Chung; Jenq, Chang-Chyi; Chang, Ming-Yang; Chen, Yung-Chang; Fang, Ji-Tseng; Yang, Chih-Wei. ACUTE KIDNEY INJURY CLASSIFICATION: COMPARISON OF AKIN AND RIFLE CRITERIA. *Shock* 33(3):p 247-252, March 2010. | DOI: 10.1097/SHK.0b013e3181b2fe0c
4. Dalakas M. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. *Expert Rev Clin Immunol.* 2022;18(7):691-701.
5. Gäckler A, Schönermarck U, Dobronravov V, et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. *BMC Nephrol.* 2021;22(1):5. doi:10.1186/s12882-020-02190-0[PubMed 33407224]
6. Hehir M, Silvestri N. Generalized myasthenia gravis. *Neurol Clin.* 2018;36:253-260.
7. Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K, Häußler V, Havla J, Hellwig K, Hümmert MW, Kleiter I, Klotz L, Krumbholz M, Kümpfel T, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Tumani H, Wildemann B, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. *J Neurol.* 2023 Jul;270(7):3341-3368. doi: 10.1007/s00415-023-11634-0. Epub 2023 Apr 6. PMID: 37022481; PMCID: PMC10267280.
8. Kulasekararaj AG, Griffin M, Langemeijer S, et al. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. *Eur J Haematol.* 2022;109(3):205-214. doi:10.1111/ejh.13783
9. Lee J, de Fontbrune F, Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naïve to complement inhibitors: the 301 study. *Blood.* 2019;133(6):530-539.
10. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. *Pediatr Nephrol.* 2016;31:15-39.
11. Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. *J Neurol.* 2023;270(8):3862-3875. doi:10.1007/s00415-023-11699-x
12. Menon D, Bril V, Pharmacotherapy of generalized myasthenia gravis with special emphasis on new biologicals. *Drugs.* 2022;82:865-887.
13. Narayanaswami P, Sanders D, Wolfe G, et al. International consensus guidance for management of myasthenia gravis. 2020 update. *Neurology.* 2021;96:114-122.
14. Nayer A, Asif A, Atypical hemolytic-uremic syndrome: a clinical review. *Am J Ther.* 2016;23(1):e151-e158.
15. Patriquin C, Kiss T, Caplan S, et al. How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. *Eur J Haematol.* 2019;102:36-52.
16. Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Yountz M, Allen K, Mashhoon Y, Kim HJ. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. *Ann Neurol.* 2023 Jun;93(6):1053-1068. doi: 10.1002/ana.26626. Epub 2023 Apr 5. PMID: 36866852.
17. Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. *Ther Apher Dial.* 2019;23(1):4-21.

18. Rondeau E, Scully M, Ariceta G, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. *Kidney Int.* 2020;97:1287-1296.
19. Röth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. *Blood Adv.* 2018;2(17):2176-2185. doi:10.1182/bloodadvances.2018020644[PubMed 30171081]
20. Tanaka K, Adams B, Aris A, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. *Pediatr Nephrol.* 2021;36:889-898.
21. Tomazos I, Sierra JR, Johnston KM, Cheung A, Brodsky RA, Weitz IC. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. *Hematology.* 2020;25(1):327-334. doi:10.1080/16078454.2020.1807226[PubMed 32856539]
22. Ultomiris (ravulizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals Inc; June 2024.
23. Ultomiris (ravulizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals; February 2024.
24. Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. *NEJM Evid.* 2022;1(5):1-12.
25. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology.* 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19. PMID: 26092914; PMCID: PMC4515040.
26. Yenerel M, deFontbrune F, Piatek C, et al. Phase 3 study of subcutaneous versus intravenous ravulizumab in eculizumab-experienced adult patients with PNH: primary analysis and 1-year follow-up. *Adv Ther.* 2023;40:211-232.

### Clinical Guideline Revision / History Information

Original Date: 3/21/2024

Reviewed/Revised: 12/02/2024